Evidence map›Paper›PMID 34431013›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021

SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature.

Lorenzo Saraceno, Emanuela Laura Susani, Maria Raffaella Marazzi, Maria Cristina Moioli, Elio Clemente Agostoni, Alessandra Protti

Open access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lorenzo SaracenoASST Grande Ospedale Metropolitano Niguarda, Department of Neurosciences, Multiple Sclerosis Center, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy. lorsaraceno@gmail.com.ORCID http://orcid.org/0000-0002-0794-8406
Emanuela Laura SusaniASST Grande Ospedale Metropolitano Niguarda, Department of Neurosciences, Multiple Sclerosis Center, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy.
Maria Raffaella MarazziASST Grande Ospedale Metropolitano Niguarda, Department of Neurosciences, Multiple Sclerosis Center, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy.
Maria Cristina MoioliASST Grande Ospedale Metropolitano Niguarda, Infectious Diseases Unit, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy.
Elio Clemente AgostoniASST Grande Ospedale Metropolitano Niguarda, Department of Neurosciences, Multiple Sclerosis Center, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy.
Alessandra ProttiASST Grande Ospedale Metropolitano Niguarda, Department of Neurosciences, Multiple Sclerosis Center, Piazza dell'Ospedale Maggiore 3, 20162, Milan, Italy.
Ospedale Maggiore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Literature data reporting SARS-CoV-2 infection in multiple sclerosis (MS) patients recently treated with immunodepleting agents as cladribine and alemtuzumab are very limited. The relationship between iatrogenic immunodeficiency and risk related to SARS-CoV-2 infection and its severe complications is still not clear. Cautiously, the start of immunosuppressant drugs as alemtuzumab and cladribine during the current COVID-19 pandemic is not recommended unless treatment benefits significantly outweigh potential risks. We report the case of a 30-year-old female MS patient infected by SARS-CoV-2 virus 4 months after alemtuzumab II cycle, while she was still leukopenic and lymphopenic. She had no complications and also presented milder COVID-related signs and symptoms as compared to her coinfected relatives (father, mother and her partner). Anti-S1 and S2 SARS-CoV-2 antibodies, tested 1 month and a half after the infection, resulted positive. We review all cases reported in literature of SARS-CoV-2 infection in MS patients treated with alemtuzumab. None of them had complications or severe disease.

Indexed as

COVID-19Multiple SclerosisAdultAlemtuzumabFemaleHumansPandemicsSARS-CoV-2AlemtuzumabAlemtuzumabCladribineCoronavirusImmunodepleting agentsMultiple sclerosisSARS-CoV-2

Identifiers

PMID34431013
PMCPMC8384460
OpenAlexW3195098688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.